Cellectis ( Cellectis )

Cellectis

Cellectis's picture

Cellectis a biopharmaceutical company focused on developing immunotherapies based on genome-edited CAR T-cells (UCARTs).[1] Cellectis was founded in 1999 and designs novel products including immune therapies for cancer and enzymes which can add DNA at targeted places in genomes.

Cellectis press release, blog etc

05/22/2018 - 14:14 Calyxt Announces Successful Closing of $60.9 Million Public Offering
05/22/2018 - 12:18 Approval of UCART123 Amendment in AML to Accelerate Clinical Development
05/21/2018 - 04:35 Calyxt Announces Full Exercise of Underwriters Option to Purchase Additional Shares
05/18/2018 - 06:04 Calyxt Announces Upsizing and Pricing of Follow-On Offering
05/15/2018 - 15:34 Calyxt Announces Launch of Proposed Follow-On Offering
05/10/2018 - 14:32 Cellectis to Present Data at the 2018 ASGCT Annual Meeting
05/02/2018 - 17:57 Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL)
05/01/2018 - 07:09 Harvards Wyss Institute partners with Cellectis to recode the human genome
04/11/2018 - 00:30 Cellectis to Present Data at the 2018 AACR Annual Meeting
04/10/2018 - 17:51 Cellectis Announces Closing of Follow-On Offering
04/09/2018 - 10:19 Allogene Therapeutics Completes Agreement for Pfizers Allogeneic CAR T Immuno-oncology Portfolio
04/04/2018 - 00:34 Cellectis Announces Pricing of Follow-On Offering
04/03/2018 - 15:13 Cellectis Announces Launch of Follow-On Offering
04/03/2018 - 10:02 Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies
03/13/2018 - 12:22 Dr. Mathieu Simon to Retire as Cellectis Chief Operating Officer; Elsy Boglioli Named as Successor
03/08/2018 - 18:25 Servier and Pfizer Announce Results of UCART19 First-in-Human Trials to Be Presented at the 44th EBMT (European Society for Blood and Marrow Transplantation) Annual Meeting
02/13/2018 - 00:55 Two Issued U.S. Patents Granted to Cellectis for CRISPR Use in T-Cells
12/12/2017 - 20:16 Preliminary Data from Servier and Pfizers UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials